FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1893-1906 November 13, 2003 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Mann, D. L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.

Methods Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause.

Results During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group (hazard ratio in the valsartan group as compared with the captopril group, 1.00; 97.5 percent confidence interval, 0.90 to 1.11; P=0.98; hazard ratio in the valsartan-and-captopril group as compared with the captopril group, 0.98; 97.5 percent confidence interval, 0.89 to 1.09; P=0.73). The upper limit of the one-sided 97.5 percent confidence interval for the comparison of the valsartan group with the captopril group was within the prespecified margin for noninferiority with regard to mortality (P=0.004) and with regard to the composite end point of fatal and nonfatal cardiovascular events (P<0.001). The valsartan-and-captopril group had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group.

Conclusions Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival.

Source Information

From the Cardiovascular Division, Brigham and Women's Hospital, Boston (M.A.P., S.D.S.); the Department of Cardiology, Western Infirmary, Glasgow, Scotland (J.J.V.M.); the Duke University Medical Center, Durham, N.C. (E.J.V., J.D.L., M.A.S., R.M.C.); the Montreal Heart Institute, Montreal (J.-L.R.); the Department of Cardiology, Rigshospitalet, Copenhagen, Denmark (L.K.); the Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy (A.P.M.); the Department of Medicine, Sahlgrenska University Hospital–Östra, Göteborg, Sweden (K.S.); the Leuven Coordinating Center, Leuven, Belgium (F.V.W.); the Cardiology Department, Green Lane Hospital, Auckland, New Zealand (H.W.); Medical Pharmaceutical Consultants, Randolph, N.J. (M.H.); and Novartis Pharmaceuticals, East Hanover, N.J. (S.E., S.Z.).

Address reprint requests to Dr. Pfeffer at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at mpfeffer{at}rics.bwh.harvard.edu.

Full Text of this Article

Related Letters:

Valsartan, Captopril, or Both in Myocardial Infarction
McAnulty J. H. Jr., Moshenyat R., Kupfer Y., Tessler S., Jorde U. P., Pfeffer M. A., McMurray J. J.V., Califf R. M.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:943-945, Feb 26, 2004. Correspondence

This article has been cited by other articles:

• Buchner, N., Banas, B., Kramer, B. K., Messerli, F. H., Bangalore, S., Ram, V. S., McMurray, J. J.V. (2008). Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events. NEJM 359: 426-427 [Full Text]  
• Dimmeler, S., Leri, A. (2008). Aging and Disease as Modifiers of Efficacy of Cell Therapy. Circ. Res. 102: 1319-1330 [Abstract] [Full Text]  
• Werner, C. M., Bohm, M. (2008). Review: The therapeutic role of RAS blockade in chronic heart failure. Therapeutic Advances in Cardiovascular Disease 2: 167-177 [Abstract]  
• Prisant, L. M., Thomas, K. L., Lewis, E. F., Huang, Z., Francis, G. S., Weaver, W. D., Pfeffer, M. A., McMurray, J. J.V., Califf, R. M., Velazquez, E. J. (2008). Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. J Am Coll Cardiol 51: 1865-1871 [Abstract] [Full Text]  
• Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., Hong, Y. (2008). Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117: 2544-2565 [Abstract] [Full Text]  
• McMurray, J. J.V. (2008). ACE Inhibitors in Cardiovascular Disease -- Unbeatable?. NEJM 358: 1615-1616 [Full Text]  
• The ONTARGET Investigators, (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 358: 1547-1559 [Abstract] [Full Text]  
• Albert, N. M., Lewis, C. (2008). Recognizing and Managing Asymptomatic Left Ventricular Dysfunction: After Myocardial Infarction. Crit Care Nurse 28: 20-37 [Full Text]  
• Setoguchi, S., Glynn, R. J., Avorn, J., Mittleman, M. A., Levin, R., Winkelmayer, W. C. (2008). Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge: A 10-Year Trend Analysis. J Am Coll Cardiol 51: 1247-1254 [Abstract] [Full Text]  
• Lewis, E. F., Velazquez, E. J., Solomon, S. D., Hellkamp, A. S., McMurray, J. J.V., Mathias, J., Rouleau, J.-L., Maggioni, A. P., Swedberg, K., Kober, L., White, H., Dalby, A. J., Francis, G. S., Zannad, F., Califf, R. M., Pfeffer, M. A. (2008). Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 29: 748-756 [Abstract] [Full Text]  
• Reynolds, H. R., Hochman, J. S. (2008). Cardiogenic Shock: Current Concepts and Improving Outcomes. Circulation 117: 686-697 [Full Text]  
• Nahrendorf, M., Aikawa, E., Figueiredo, J.-L., Stangenberg, L., van den Borne, S. W., Blankesteijn, W. M., Sosnovik, D. E., Jaffer, F. A., Tung, C.-H., Weissleder, R. (2008). Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 29: 445-454 [Abstract] [Full Text]  
• Li, P., Kondo, T., Numaguchi, Y., Kobayashi, K., Aoki, M., Inoue, N., Okumura, K., Murohara, T. (2008). Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis. Hypertension 51: 252-258 [Abstract] [Full Text]  
• van Domburg, R. T., Hoeks, S. E., Welten, G. M.J.M., Chonchol, M., Elhendy, A., Poldermans, D. (2008). Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. J. Am. Soc. Nephrol. 19: 158-163 [Abstract] [Full Text]  
• Perticone, F., Maio, R., Sciacqua, A., Andreozzi, F., Iemma, G., Perticone, M., Zoccali, C., Sesti, G. (2008). Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension. Diabetes 57: 167-171 [Abstract] [Full Text]  
• Thune, J. J., Signorovitch, J., Kober, L., Velazquez, E. J., McMurray, J. J.V., Califf, R. M., Maggioni, A. P., Rouleau, J. L., Howlett, J., Zelenkofske, S., Pfeffer, M. A., Solomon, S. D. (2008). Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension 51: 48-54 [Abstract] [Full Text]  
• Isbell, D. C., Voros, S., Yang, Z., DiMaria, J. M., Berr, S. S., French, B. A., Epstein, F. H., Bishop, S. P., Wang, H., Roy, R. J., Kemp, B. A., Matsubara, H., Carey, R. M., Kramer, C. M. (2007). Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 293: H3372-H3378 [Abstract] [Full Text]  
• Beanlands, R. S.B., Nichol, G., Huszti, E., Humen, D., Racine, N., Freeman, M., Gulenchyn, K. Y., Garrard, L., deKemp, R., Guo, A., Ruddy, T. D., Benard, F., Lamy, A., Iwanochko, R. M., the PARR-2 Investigators{ddagger}{ddagger}, (2007). F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease: A Randomized, Controlled Trial (PARR-2). J Am Coll Cardiol 50: 2002-2012 [Abstract] [Full Text]  
• Parikh, N. I., Gona, P., Larson, M. G., Wang, T. J., Newton-Cheh, C., Levy, D., Benjamin, E. J., Kannel, W. B., Vasan, R. S. (2007). Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28: 2644-2652 [Abstract] [Full Text]  
• Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., Krumholz, H. M. (2007). Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. Arch Intern Med 167: 1930-1936 [Abstract] [Full Text]  
• Jacquier, A., Higgins, C. B., Martin, A. J., Do, L., Saloner, D., Saeed, M. (2007). Injection of Adeno-associated Viral Vector Encoding Vascular Endothelial Growth Factor Gene in Infarcted Swine Myocardium: MR Measurements of Left Ventricular Function and Strain. Radiology 245: 196-205 [Abstract] [Full Text]  
• Verma, A., Anavekar, N. S., Meris, A., Thune, J. J., Arnold, J. M. O., Ghali, J. K., Velazquez, E. J., McMurray, J. J.V., Pfeffer, M. A., Solomon, S. D. (2007). The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction: The VALIANT Echo Study. J Am Coll Cardiol 50: 1238-1245 [Abstract] [Full Text]  
• Solomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J.V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., Pfeffer, M. A., for the Candesartan in Heart failure: Assessment o, (2007). Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation 116: 1482-1487 [Abstract] [Full Text]  
• Hall, A. S, Strauss, M. H (2007). More about the "ARB MI paradox". Heart 93: 1011-1014 [Abstract] [Full Text]  
• Azizi, M., Menard, J., Bissery, A., Guyene, T.-T., Bura-Riviere, A. (2007). Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. CJASN 2: 947-955 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 50: e28-e55 [Full Text]  
• Schiffrin, E. L., Lipman, M. L., Mann, J. F.E. (2007). Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation 116: 85-97 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Kloner, R. A., Cannom, D. S. (2007). Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices. Circulation 115: 2983-2989 [Full Text]  
• Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 0: ehm236v1-75 [Full Text]  
• Koh, K. K., Quon, M. J., Lee, Y., Han, S. H., Ahn, J. Y., Chung, W.-J., Kim, J.-a, Shin, E. K. (2007). Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 28: 1440-1447 [Abstract] [Full Text]  
• Hennekens, C. H., Pfeffer, M. A., Swedberg, K. (2007). The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. J CARDIOVASC PHARMACOL THER 12: 124-126 [Abstract]  
• Delea, T. E., Taneja, C., Moynahan, A., Thomas, S. K., Frech-Tamas, F., Oster, G. (2007). Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health Syst Pharm 64: 1187-1196 [Abstract] [Full Text]  
• Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Berghe, G. V. d., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 9: C3-C74 [Full Text]  
• Johnson, M. J (2007). Management of end stage cardiac failure. Postgrad. Med. J. 83: 395-401 [Abstract] [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761-2788 [Full Text]  
• Alexander, K. P., Newby, L. K., Armstrong, P. W., Cannon, C. P., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M. (2007). Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation 115: 2570-2589 [Abstract] [Full Text]  
• Fischer, M. A., Choudhry, N. K., Winkelmayer, W. C. (2007). Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?. Health Aff (Millwood) 26: 800-807 [Abstract] [Full Text]  
• Assmus, B., Fischer-Rasokat, U., Honold, J., Seeger, F. H., Fichtlscherer, S., Tonn, T., Seifried, E., Schachinger, V., Dimmeler, S., Zeiher, A. M. (2007). Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry. Circ. Res. 100: 1234-1241 [Abstract] [Full Text]  
• Leesar, M. A., Jneid, H., Tang, X.-L., Bolli, R. (2007). Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty.. J Am Coll Cardiol 49: 1607-1610 [Abstract] [Full Text]  
• Sampson, U. K., Pfeffer, M. A., McMurray, J. J.V., Lokhnygina, Y., White, H. D., Solomon, S. D., for the Valsartan in Acute Myocardial iNfarcTion (, (2007). Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. Eur Heart J 28: 685-691 [Abstract] [Full Text]  
• Seeger, F. H., Tonn, T., Krzossok, N., Zeiher, A. M., Dimmeler, S. (2007). Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 28: 766-772 [Abstract] [Full Text]  
• Amigoni, M., Meris, A., Thune, J. J., Mangalat, D., Skali, H., Bourgoun, M., Warnica, J. W., Barvik, S., Arnold, J. M. O., Velazquez, E. J., Van de Werf, F., Ghali, J., McMurray, J. J.V., Kober, L., Pfeffer, M. A., Solomon, S. D. (2007). Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. Eur Heart J 28: 326-333 [Abstract] [Full Text]  
• Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136 [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation 114: 2871-2891 [Full Text]  
• Struthers, A D (2006). Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart 92: 1728-1731 [Abstract] [Full Text]  
• Oprisiu-Fournier, R., Serot, J.-M., Achard, J.-M., Messerli, F. H., Black, S. E., Fournier, A. (2006). AT1 Receptor Blockers for Cognition Decline After Cardiac Surgery?. Stroke 37: 2666-2666 [Full Text]  
• Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, H., Yu, J., Corti, R., Mathey, D. G., Hamm, C. W., Suselbeck, T., Assmus, B., Tonn, T., Dimmeler, S., Zeiher, A. M., the REPAIR-AMI Investigators, (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.. NEJM 355: 1210-1221 [Abstract] [Full Text]  
• Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., Bonow, R. O. (2006). Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation 114: 1202-1213 [Full Text]  
• Hilbrich, L., Sleight, P. (2006). Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. Eur Heart J 27: 2158-2164 [Abstract] [Full Text]  
• Poole-Wilson, P. A, Lyon, A. R., Jacques, A. M. (2006). A commentary on clinical trials in chronic heart failure.. SEMIN CARDIOTHORAC VASC ANESTH 10: 242-245 [Abstract]  
• Roig, E. (2006). Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure. Eur Heart J Suppl 8: E12-E17 [Abstract] [Full Text]  
• Howard, P. A, Cheng, J. W., Crouch, M. A, Colucci, V. J, Kalus, J. S, Spinler, S. A, Munger, M. (2006). Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. The Annals of Pharmacotherapy 40: 1607-1616 [Abstract] [Full Text]  
• Strauss, M. H., Hall, A. S. (2006). Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox. Circulation 114: 838-854 [Full Text]  
• Tsuyuki, R. T., McDonald, M. A. (2006). Response to Tsuyuki and McDonald. Circulation 114: 855-860 [Full Text]  
• Granger, C. B., McMurray, J. J.V. (2006). Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song. J Am Coll Cardiol 48: 434-437 [Abstract] [Full Text]  
• McMurray, J., Swedberg, K. (2006). Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J 27: 1773-1777 [Abstract] [Full Text]  
• Kaul, S., Diamond, G. A. (2006). Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials. ANN INTERN MED 145: 62-69 [Abstract] [Full Text]  
• Winkelmayer, W. C., Charytan, D. M., Brookhart, M. A., Levin, R., Solomon, D. H., Avorn, J. (2006). Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. CJASN 1: 796-801 [Abstract] [Full Text]  
• Goldberg, L. R., Jessup, M. (2006). Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction. Circulation 113: 2851-2860 [Full Text]  
• Hennekens, C. H., Kowalczykowski, M., Hollar, D. (2006). Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and {beta}-Blockers in the Treatment of Patients With Heart Failure. J CARDIOVASC PHARMACOL THER 11: 149-152 [Abstract]  
• Lechat, P. (2006). The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Eur Heart J Suppl 8: C5-C12 [Abstract] [Full Text]  
• Smith, S. C. Jr, Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L., Jones, D., Krumholz, H. M., Mosca, L., Pasternak, R. C., Pearson, T., Pfeffer, M. A., Taubert, K. A. (2006). AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47: 2130-2139 [Full Text]  
• Smith, S. C. Jr, Allen, J., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L., Jones, D., Krumholz, H. M., Mosca, L., Pasternak, R. C., Pearson, T., Pfeffer, M. A., Taubert, K. A. (2006). AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372 [Full Text]  
• Cleland, J. G.F., Charlesworth, A., Lubsen, J., Swedberg, K., Remme, W. J., Erhardt, L., Di Lenarda, A., Komajda, M., Metra, M., Torp-Pedersen, C., Poole-Wilson, P. A., for the COMET Investigators, (2006). A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure: A Report From the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 47: 1603-1611 [Abstract] [Full Text]  
• Brady, A J B, Poole-Wilson, P A (2006). ESC-CHF: guidelines for the aspirational and the practical.. Heart 92: 437-440 [Abstract] [Full Text]  
• Volpe, M., Tocci, G., Pagannone, E. (2006). Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.. J. Am. Soc. Nephrol. 17: S36-S43 [Abstract] [Full Text]  
• Nahrendorf, M., Hu, K., Frantz, S., Jaffer, F. A., Tung, C.-H., Hiller, K.-H., Voll, S., Nordbeck, P., Sosnovik, D., Gattenlohner, S., Novikov, M., Dickneite, G., Reed, G. L., Jakob, P., Rosenzweig, A., Bauer, W. R., Weissleder, R., Ertl, G. (2006). Factor XIII Deficiency Causes Cardiac Rupture, Impairs Wound Healing, and Aggravates Cardiac Remodeling in Mice With Myocardial Infarction. Circulation 113: 1196-1202 [Abstract] [Full Text]  
• Tsouli, S. G., Liberopoulos, E. N., Kiortsis, D. N., Mikhailidis, D. P., Elisaf, M. S. (2006). Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. J CARDIOVASC PHARMACOL THER 11: 1-15 [Abstract]  
• Muller, D. N., Luft, F. C. (2006). Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage. CJASN 1: 221-228 [Abstract] [Full Text]  
• Voros, S., Yang, Z., Bove, C. M., Gilson, W. D., Epstein, F. H., French, B. A., Berr, S. S., Bishop, S. P., Conaway, M. R., Matsubara, H., Carey, R. M., Kramer, C. M. (2006). Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 290: H1004-H1010 [Abstract] [Full Text]  
• McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., Kober, L., Van de Werf, F., Califf, R., Pfeffer, M. (2006). The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction: An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47: 726-733 [Abstract] [Full Text]  
• Naumova, A. V., Chacko, V. P., Ouwerkerk, R., Stull, L., Marban, E., Weiss, R. G. (2006). Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 290: H837-H843 [Abstract] [Full Text]  
• Krumholz, H. M., Anderson, J. L., Brooks, N. H., Fesmire, F. M., Lambrew, C. T., Landrum, M. B., Weaver, W. D., Whyte, J., Bonow, R. O., Bennett, S. J., Burke, G., Eagle, K. A., Krumholz, H. M., Lambrew, C. T., Linderbaum, J., Masoudi, F. A., Normand, S.-L. T., PiNa, I. L., Radford, M. J., Rumsfeld, J. S., Ritchie, J. L., Spertus, J. A. (2006). ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 47: 236-265 [Full Text]  
• Marcy, T. R., Ripley, T. L. (2006). Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm 63: 49-58 [Abstract] [Full Text]  
• Berl, T., Henrich, W. (2006). Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. CJASN 1: 8-18 [Full Text]  
• (2005). Part 8: Stabilization of the Patient With Acute Coronary Syndromes. Circulation 112: IV-89-IV-110 [Full Text]  
• Aronow, W. S. (2005). Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. J. Gerontol. A Biol. Sci. Med. Sci. 60: 1597-1605 [Abstract] [Full Text]  
• Monteiro, P., Goncalves, L., Providencia, L. A (2005). Diabetes and cardiovascular disease: the road to cardioprotection. Heart 91: 1621-1625 [Full Text]  
• (2005). Part 5: Acute Coronary Syndromes. Circulation 112: III-55-III-72 [Full Text]  
• Verdecchia, P., Angeli, F., Gattobigio, R., Reboldi, G. P. (2005). Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 26: 2381-2386 [Abstract] [Full Text]  
• van de Wal, R. M.A., van Veldhuisen, D. J., van Gilst, W. H., Voors, A. A. (2005). Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J 26: 2361-2367 [Abstract] [Full Text]